Literature DB >> 24435167

Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.

Klaus Fortschegger1, Stefanie Anderl, Dagmar Denk, Sabine Strehl.   

Abstract

UNLABELLED: PAX5, a transcription factor pivotal for B-cell commitment and maintenance, is one of the most frequent targets of somatic mutations in B-cell precursor acute lymphoblastic leukemia. A number of PAX5 rearrangements result in the expression of in-frame fusion genes encoding chimeric proteins, which at the N-terminus consistently retain the PAX5 DNA-binding paired domain fused to the C-terminal domains of a markedly heterogeneous group of fusion partners. PAX5 fusion proteins are thought to function as aberrant transcription factors, which antagonize wild-type PAX5 activity. To gain mechanistic insight into the role of PAX5 fusion proteins in leukemogenesis, the biochemical and functional properties of uncharacterized fusions: PAX5-DACH1, PAX5-DACH2, PAX5-ETV6, PAX5-HIPK1, and PAX5-POM121 were ascertained. Independent of the subcellular distribution of the wild-type partner proteins, ectopic expression of all PAX5 fusion proteins showed a predominant nuclear localization, and by chromatin immunoprecipitation all of the chimeric proteins exhibited binding to endogenous PAX5 target sequences. Furthermore, consistent with the presence of potential oligomerization motifs provided by the partner proteins, the self-interaction capability of several fusion proteins was confirmed. Remarkably, a subset of the PAX5 fusion proteins conferred CD79A promoter activity; however, in contrast with wild-type PAX5, the fusion proteins were unable to induce Cd79a transcription in a murine plasmacytoma cell line. These data show that leukemia-associated PAX5 fusion proteins share some dominating characteristics such as nuclear localization and DNA binding but also show distinctive features. IMPLICATIONS: This comparative study of multiple PAX5 fusion proteins demonstrates both common and unique properties, which likely dictate their function and impact on leukemia development. Mol Cancer Res; 12(4); 595-606. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24435167     DOI: 10.1158/1541-7786.MCR-13-0337

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  16 in total

1.  PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia.

Authors:  Yanara Marincevic-Zuniga; Vasilios Zachariadis; Lucia Cavelier; Anders Castor; Gisela Barbany; Erik Forestier; Linda Fogelstrand; Mats Heyman; Jonas Abrahamsson; Gudmar Lönnerholm; Ann Nordgren; Ann-Christine Syvänen; Jessica Nordlund
Journal:  Haematologica       Date:  2015-10-22       Impact factor: 9.941

2.  Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia.

Authors:  Grazia Fazio; Giulia Daniele; Valeria Cazzaniga; Luciana Impera; Marco Severgnini; Ilaria Iacobucci; Marta Galbiati; Anna Leszl; Ingrid Cifola; Gianluca De Bellis; Paola Bresciani; Giovanni Martinelli; Giuseppe Basso; Andrea Biondi; Clelia Tiziana Storlazzi; Giovanni Cazzaniga
Journal:  Haematologica       Date:  2014-10-10       Impact factor: 9.941

Review 3.  Nucleoporin genes in human diseases.

Authors:  Valeria Nofrini; Danika Di Giacomo; Cristina Mecucci
Journal:  Eur J Hum Genet       Date:  2016-04-13       Impact factor: 4.246

Review 4.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

5.  Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.

Authors:  Leonie Smeenk; Maria Fischer; Sabine Jurado; Markus Jaritz; Anna Azaryan; Barbara Werner; Mareike Roth; Johannes Zuber; Martin Stanulla; Monique L den Boer; Charles G Mullighan; Sabine Strehl; Meinrad Busslinger
Journal:  EMBO J       Date:  2017-02-20       Impact factor: 11.598

6.  POM121 is a novel marker for predicting the prognosis of laryngeal cancer.

Authors:  Ruihua Zhao; Genxiong Tang; Tengqi Wang; Lingli Zhang; Wei Wang; Qiangfang Zhao; Kun Zhao
Journal:  Histol Histopathol       Date:  2020-10-05       Impact factor: 2.303

7.  Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

Authors:  Claire Schwab; Karin Nebral; Lucy Chilton; Cristina Leschi; Esmé Waanders; Judith M Boer; Markéta Žaliová; Rosemary Sutton; Ingegerd Ivanov Öfverholm; Kentaro Ohki; Yuka Yamashita; Stefanie Groeneveld-Krentz; Eva Froňková; Marleen Bakkus; Joelle Tchinda; Thayana da Conceição Barbosa; Grazia Fazio; Wojciech Mlynarski; Agata Pastorczak; Giovanni Cazzaniga; Maria S Pombo-de-Oliveira; Jan Trka; Renate Kirschner-Schwabe; Toshihiko Imamura; Gisela Barbany; Martin Stanulla; Andishe Attarbaschi; Renate Panzer-Grümayer; Roland P Kuiper; Monique L den Boer; Hélène Cavé; Anthony V Moorman; Christine J Harrison; Sabine Strehl
Journal:  Blood Adv       Date:  2017-08-14

Review 8.  The role of Pax5 in leukemia: diagnosis and prognosis significance.

Authors:  Mohammad Shahjahani; Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Farzaneh Tavakoli; Ali Amin Asnafi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

9.  The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Authors:  Dagmar Schinnerl; Klaus Fortschegger; Maximilian Kauer; João R M Marchante; Reinhard Kofler; Monique L Den Boer; Sabine Strehl
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

10.  PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Authors:  Zhaohui Gu; Michelle L Churchman; Kathryn G Roberts; Ian Moore; Xin Zhou; Joy Nakitandwe; Kohei Hagiwara; Stephane Pelletier; Sebastien Gingras; Hartmut Berns; Debbie Payne-Turner; Ashley Hill; Ilaria Iacobucci; Lei Shi; Stanley Pounds; Cheng Cheng; Deqing Pei; Chunxu Qu; Scott Newman; Meenakshi Devidas; Yunfeng Dai; Shalini C Reshmi; Julie Gastier-Foster; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; William L Carroll; Patrick A Zweidler-McKay; Karen R Rabin; Leonard A Mattano; Kelly W Maloney; Alessandro Rambaldi; Orietta Spinelli; Jerald P Radich; Mark D Minden; Jacob M Rowe; Selina Luger; Mark R Litzow; Martin S Tallman; Janis Racevskis; Yanming Zhang; Ravi Bhatia; Jessica Kohlschmidt; Krzysztof Mrózek; Clara D Bloomfield; Wendy Stock; Steven Kornblau; Hagop M Kantarjian; Marina Konopleva; Williams E Evans; Sima Jeha; Ching-Hon Pui; Jun Yang; Elisabeth Paietta; James R Downing; Mary V Relling; Jinghui Zhang; Mignon L Loh; Stephen P Hunger; Charles G Mullighan
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.